Mutations in EGFR have been implicated in the pathogenesis of various types of cancer, and therefore antibody therapy directed against the epidermal growth factor receptor (egfr) is increasingly being used in the management of various cancers. Currently, anti-egfr antibodies are used mainly in the management of cancers of the head and neck and metastatic colorectal cancers. Because of this increasing use, we would like to inform the oncology community in North America of a rare, but life-threatening, toxicity associated with anti-egfr antibody therapy. Although cases in white and Japanese men have been documented, we present the first known North American report of panitumumab-induced pulmonary toxicity in a white woman.

SDH (succinate dehydrogenase)-deficient renal cancer is a rare renal cancer (RCC) subtype recently accepted by WHO as an unique RCC subtype with only 59 cases described worldwide. Here we report a case of 17-year old man. The detailed evaluation indicated occurrence of the SDHBdeficient RCC. The genetic testing revealed no germline mutation in SDH genes. Immunohistochemistry showed SDHB deficiency, overexpression of PKM2 and dramatic downregulation of FBP1 metabolic enzymes, unaltered levels of pAMPK and mTOR. Furthermore, the strong upregulation of INI1, BRG1 and overexpression of BAF180 subunits of SWI/SNF ATP-dependent chromatin remodeling complex were found. The identified tumor pathologically did not resemble ccRCC (clear cell renal cell carcinoma) but some metabolic alterations are common for both cancer types. Thus, we postulate that the phenotypical differences between ccRCC and SDHB-deficient RCC may be related to distinct molecular and metabolic alterations.

The authors report a case of hepatocellular carcinoma in which extended right hepatic lobectomy was performed with reconstruction of the inferior vena cava without use of peripheral arteriovenous fistula.

Retrohepatic vena cava surgery was performed in nine patients with renal cell carcinoma and with a propagation of the neoplastic thrombus into the inferior vena cava (IVC) up to the confluence with hepatic veins or to the right heart. Surgical treatment consisted of simultaneous radical nephrectomy and exploration of the retrohepatic vena cava with careful removal under direct vision of the thrombus, which was attached to the intima. In two patients cardiopulmonary bypass was used. All procedures were performed under IVC exclusion. Five patients are still alive from 2 up to 48 months after surgery. Surgical technique and postoperative management including vascular complications are discussed.From the *3rd

Authors' contribution Wkład autorów: A. Study design/planning zaplanowanie badań B. Data collection/entry zebranie danych C. Data analysis/statistics dane -analiza i statystyki D. Data interpretation interpretacja danych E. Preparation of manuscript przygotowanie artykułu F. Literature analysis/search wyszukiwanie i analiza literatury G. Funds collection zebranie funduszy SummaryThe following case study presents a rare advanced penile cancer in a 52 year-old man. The diagnosis of penile cancer is not especially common. Patient with squamous cell carcinoma, which is the most prevalent type of penile cancer, undergo surgical treatment. The first part of the therapy covers a radical penectomy, and the second one − radical pelvic lymphadenectomy. Despite such a drastic surgical procedure, there was a need of further oncological treatment including an adjuvant chemotherapy. Unfortunately, the patient did not continue his treatment. Such advanced stages of penile cancer are very uncommon because of patients being aware of any changes in the genitourinary area. In the early stages of the disease, an isolated resection of penile change or a partial penectomy is usually a sufficient consideration. In such cases, overall survival rates are high. However, more advanced stages typically require a more radical treatment and a systemic approach including chemotherapy and radiotherapy. Then, the results of treatment and prognosis for the patients are not as good as in case of patients with early diagnosed problems. StreszczeniePoniższe studium przypadku przedstawia rzadkiego zaawansowanego raka prącia u 52-letniego mężczyzny. Rozpoznanie raka prącia nie jest szczególnie powszechne. Pacjent z rakiem płaskonabłonkowym, który jest najczęściej występującym rakiem prącia, przechodzi leczenie chirurgiczne. Pierwsza część terapii obejmuje radykalną penektomię, a druga radykalną limfadenektomię miednicy. Pomimo tak drastycznej procedury chirurgicznej, konieczne było dalsze leczenie onkologiczne, w tym chemioterapia adjuwantowa. Niestety, pacjent nie kontynuował leczenia. Takie zaawansowane stadium raka prącia jest bardzo rzadkie, ponieważ pacjenci są świadomi jakichkolwiek zmian w obszarze moczowopłciowym. We wczesnych stadiach choroby zwykle wystarczająca jest resekcja zmiany prącia lub częściowa penektomia. W takich przypadkach ogólne wskaźniki przeżycia są wysokie. Jednak bardziej zaawansowane stadia wymagają zazwyczaj bardziej radykalnego leczenia i podejścia systemowego, w tym chemioterapii i radioterapii. Wyniki leczenia i rokowania dla tych pacjentów nie są tak dobre, jak w przypadku pacjentów z wczesną diagnozą.Słowa kluczowe: nowotwory prącia, rak, płaskonabłonkowy, wycięcie węzłów chłonnych Mika P, Kisiel M. A rare clinical case of an advanced penile cancer in a 52 year-old man. Health Prob Civil. 2017; 11(4): 247-252.